{"id":"W2099259685","doi":"10.1093/annonc/mdi310","title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":301,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bayer (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Toxicity; Adverse effect; Kinase; Internal medicine; Bay; Pharmacology; Refractory (planetary science); Tyrosine-kinase inhibitor; Cancer; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007216412,0.001346553,0.002069103,0.0003629276,0.0004466952,0.0008426796,0.000663846,0.0009903872,0.002893854],"category_scores_gemma":[0.0008352256,0.0006437227,0.001028204,0.0003989686,0.00101592,0.0008056667,0.0002252509,0.003881328,0.0007625729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009018059,"about_ca_system_score_gemma":0.001784212,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001354784,"about_ca_topic_score_gemma":0.002681493,"domain_scores_codex":[0.9997494,0.00009831294,0.000008405795,0.00004972716,0.00002393175,0.00007020917],"domain_scores_gemma":[0.999261,0.0001157159,0.0001473209,0.00006737437,0.00003300767,0.000375538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7513065,0.07048776,0.006813663,0.0003273947,0.0009629992,0.0003373265,0.0002748891,0.003967244,0.08132476,0.0004959251,0.003961244,0.07974026],"study_design_scores_gemma":[0.4222872,0.5510301,0.01449409,0.00001863869,0.0004278074,0.000450709,0.00006383799,0.002317866,0.005918814,0.0003763704,0.00257912,0.00003550657],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995596,0.0008768265,0.0005456453,0.0002938801,0.00008081156,0.0007811275,0.0005781588,0.00008269568,0.001164944],"genre_scores_gemma":[0.9927766,0.0009097505,0.001236535,0.0004529625,0.0001626886,0.001104665,0.001161704,0.0000378657,0.002157218],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002893854,"threshold_uncertainty_score":0.009680927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03243005053116366,"score_gpt":0.3398462573339467,"score_spread":0.307416206802783,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}